Evolus, Inc.: Soleus Capital Master Fund, L.P. amends Schedule 13G stake filing
Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 9 November 2026, by SEC EDGAR SCHEDULE 13G
25
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Soleus Capital Master Fund, L.P. amended its Schedule 13G stake filing for Evolus, Inc., according to SEC accession 0001213900-26-117547. The filing updates the fund's reported ownership position in the aesthetic medicine company. The specific size of the stake and any change from prior disclosures were not detailed in the headline. Investors should watch for further 13G amendments or 13D filings that could signal a shift in activist or passive interest.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Evolus, Inc., Soleus Capital Master Fund, L.P.